Form 4: Lenz Therapeutics CFO Daniel Chevallard Reports Acquisition of Common Stock
SEC Form 4 Filing
Daniel R. Chevallard, CFO of Lenz Therapeutics, acquired 3,188 shares of common stock on May 14, 2024.
Summary
- On May 15, 2024, a Form 4 filing was submitted to the SEC regarding Daniel R. Chevallard, the Chief Financial Officer of Lenz Therapeutics, Inc.
- The filing reports a transaction that occurred on May 14, 2024, where Chevallard acquired 3,188 shares of Lenz Therapeutics' common stock.
- The price per share was $15.68.
- Following the reported transaction, Chevallard directly owns 3,188 shares of common stock.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard disclosure of stock acquisition by an officer. While insider buying can be seen as positive, it's a single transaction and doesn't provide a strong signal.
Positives
- The CFO's purchase of company stock could be interpreted as a positive signal, indicating confidence in the company's future prospects.
Industry Context
This filing is a routine disclosure of insider trading activity, which is common for publicly traded companies. It provides transparency into the actions of company executives.
Stakeholder Impact
- Shareholders may view the CFO's stock purchase as a positive sign of confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 05/14/2024 | Date of transaction: Daniel R. Chevallard acquired 3,188 shares of common stock. |
| 05/15/2024 | Date of Form 4 filing with the SEC. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.